Citations

Clear

1727 citation(s) found for "So, Alan".

Biomarkers Enhance Discrimination and Prognosis of Type 2 Myocardial Infarction
Horiuchi, Yu , Wettersten, Nicholas , Patel, Mitul , Mueller, Christian, Neath, Sean‐Xavier , Christenson, Robert H. , Morgenthaler, Nils G., McCord, James , Nowak, Richard M. , Vilke, Gary M. , Daniels, Lori B. , Apple, Fred S. , Cannon, Chad , Nagurney, John Tobias , Schreiber, Donald , Diercks, Deborah B. , Headden, Gary , Limkakeng, Alexander T. , Wu, Alan H.B. , Ebmeyer, Stefan , Jaffe, Allan S. , Peacock, W. Frank, Maisel, Alan , Müller, Christian , Mueller, Christian , Daniels, Lori B , Hollander, Judd E. , deFilippi, Christopher R. , Hogan, Christopher J. , Anand, Inder S. , Jaffe, Allan S.

Mayo Clinic

Circulation | August 21, 2020 | Volume: 142 | Issue: 16 | Pages: 1532-1544

10.1161/circulationaha.120.046682 | PMID 32820656 Get It

Background: The observed incidence of type 2 myocardial infarction (T2MI) is expected to increase with the implementation of increasingly sensitive cTn assays. However, it remains to be determined how to diagnose, risk-stratify, and treat patients with T2MI. We aimed to discriminate and risk-stratify T2MI using biomarkers. Methods: Patients presenting to the emergency department with chest pain, enrolled in the CHOPIN study (Copeptin Helps in the early detection Of Patients with acute myocardial INfarction), were retrospectively analyzed. Two cardiologists adjudicated type 1 MI (T1MI) and T2MI. The prognostic ability of several biomarkers alone or in combination to discriminate T2MI from T1MI was investigated using receiver operating characteristic curve analysis. The biomarkers analyzed were cTnI, copeptin, MR-proANP (midregional proatrial natriuretic peptide), CT-proET1 (C-terminal proendothelin-1), MR-proADM (midregional proadrenomedullin), and procalcitonin. The prognostic utility of these biomarkers for all-cause mortality and major adverse cardiovascular event (a composite of acute myocardial infarction, unstable angina pectoris, reinfarction, heart failure, and stroke) at 180-day follow-up was also investigated. Results: Among the 2071 patients, T1MI and T2MI were adjudicated in 94 and 176 patients, respectively. Patients with T1MI had higher levels of baseline cTnI, whereas those with T2MI had higher baseline levels of MR-proANP, CT-proET1, MR-proADM, and procalcitonin. The area under the receiver operating characteristic curve for the diagnosis of T2MI was higher for CT-proET1, MR-proADM, and MR-proANP (0.765, 0.750, and 0.733, respectively) than for cTnI (0.631). Combining all biomarkers resulted in a similar accuracy to a model using clinical variables and cTnI (0.854 versus 0.884, P =0.294). Addition of biomarkers to the clinical model yielded the highest area under the receiver operating characteristic curve (0.917). Other biomarkers, but not cTnI, were associated with mortality and major adverse cardiovascular event at 180 days among all patients, with no interaction between the diagnosis of T1MI or T2MI. Conclusions: Assessment of biomarkers reflecting pathophysiologic processes occurring with T2MI might help differentiate it from T1MI. All biomarkers measured, except cTnI, were significant predictors of prognosis, regardless of the type of myocardial infarction.
Development of Entrustable Professional Activities for Advanced Inflammatory Bowel Disease Fellowship Training in the United States
Cohen, Benjamin L, Gallinger, Zane , Ha, Christina , Holubar, Stefan D. , Hou, Jason K. , Kinnucan, Jami , Mahadevan, Uma, Moss, Alan C. , Raffals, Laura E. , Szigethy, Eva , Wolf, Douglas C. , Dubinsky, Marla C. , Shah, Brijen J. , Ehrlich, Orna , Holubar, Stefan D , Cohen, Benjamin L, Regueiro, Miguel , Patel, Anish A , Hanauer, Stephen B.

Mayo Clinic

Inflammatory Bowel Diseases | August 21, 2020 | Volume: 26 | Issue: 9 | Pages: 1291-1305

10.1093/ibd/izaa177 | PMID 32820340 Get It

Abstract Background The level of inflammatory bowel disease (IBD) training in general gastroenterology fellowship is often insufficient to prepare trainees to deliver advanced IBD care in practice. Advanced IBD fellowships have been developed to fill this training gap, but there is no established curriculum, and significant variability exists across programs. Entrustable professional activities (EPAs) are practical and realistic objectives that define essential tasks of a specialty that physicians should master to be competent during independent practice. The American College of Gastroenterology (ACG) and Crohn’s & Colitis Foundation (Foundation) established a task force to develop and appraise EPAs for advanced IBD fellowship. Methods Entrustable professional activities were developed using a multistep approach in a similar manner to other specialties. Initial EPAs identified via focus groups were evaluated, critiqued, and changed using an iterative model of feedback. The final EPAs were selected after the task force conducted a 3-phase modified Delphi method consisting of 2 sequential rounds of web-based voting and an in-person consensus meeting. Results Ten EPAs for advanced IBD fellowship were established including detailed descriptions with the associated knowledge, skills, and attitudes for each that can serve as curricular milestones. Conclusion Ten EPAs describing the core work of an advanced IBD fellowship–trained physician have been established by a multisociety task force. Creating EPAs for an advanced curriculum comes with unique challenges, particularly the need to prevent duplication of prior training competencies while demonstrating the potential for unique milestones.
IGF-Binding Proteins, Adiponectin, and Survival in Metastatic Colorectal Cancer: Results From CALGB (Alliance)/SWOG 80405
Guercio, Brendan J. , Zhang, Sui , Ou, Fang‐Shu , Venook, Alan P. , Niedzwiecki, Donna , Lenz, Heinz‐Josef , Innocenti, Federico , Pollak, Michaël , Nixon, Andrew B. , Mullen, Brian C, O’Neil, Bert H. , Polite, Blasé N. , Benson, Al B. , Atkins, James N., Goldberg, Richard M. , Blanke, Charles D. , Fuchs, Charles S. , Meyerhardt, Jeffrey A. , Pollak, Michael N , Goldberg, Richard M , Brown, Justin C , Fuchs, Charles S , Meyerhardt, Jeffrey A , Venook, Alan P , Ou, Fang-Shu , Nixon, Andrew B , Niedzwiecki, Donna , Shaw, James Edward , Brown, Justin C. , O’Reilly, Eileen M. , Mayer, Robert J.

Mayo Clinic

JNCI Cancer Spectrum | August 19, 2020 | Volume: 5 | Issue: 1 | Pages: No page available

10.1093/jncics/pkaa074 | PMID 33426464 Get It

AbstractBackgroundEnergy balance-related biomarkers are associated with risk and prognosis of various malignancies. Their relationship to survival in metastatic colorectal cancer (mCRC) requires further study.MethodsBaseline plasma insulin-like growth factor (IGF)-1, IGF-binding protein (IGFBP)-3, IGFBP-7, C-peptide, and adiponectin were measured at time of trial registration in a prospective cohort of patients with mCRC participating in a National Cancer Institute–sponsored trial of first-line systemic therapy. We used Cox proportional hazards regression to adjust for confounders and examine associations of each biomarker with overall survival (OS) and progression-free survival (PFS). P values are 2-sided.ResultsMedian follow-up for 1086 patients was 6.2 years. Compared with patients in the lowest IGFBP-3 quintile, patients in the highest IGFBP-3 quintile experienced an adjusted hazard ratio (HR) for OS of 0.57 (95% confidence interval [CI] = 0.42 to 0.78; Pnonlinearity < .001) and for PFS of 0.61 (95% CI = 0.45 to 0.82; Ptrend = .003). Compared with patients in the lowest IGFBP-7 quintile, patients in the highest IGFBP-7 quintile experienced an adjusted hazard ratio for OS of 1.60 (95% CI = 1.30 to 1.97; Ptrend < .001) and for PFS of 1.38 (95% CI = 1.13 to 1.69; Ptrend < .001). Plasma C-peptide and IGF-1 were not associated with patient outcomes. Adiponectin was not associated with OS; there was a nonlinear U-shaped association between adiponectin and PFS (Pnonlinearity = .03).ConclusionsAmong patients with mCRC, high plasma IGFBP-3 and low IGFBP-7 were associated with longer OS and PFS. Extreme levels of adiponectin were associated with shorter PFS. These findings suggest potential avenues for prognostic and therapeutic innovation.
Rucaparib in Men With Metastatic Castration-Resistant Prostate Cancer Harboring a BRCA1 or BRCA2 Gene Alteration
Abida, Wassim , Patnaik, Akash , Campbell, David , Shapiro, Jeremy , Bryce, Alan H. , McDermott, Ray , Sautois, Brieuc , Bambury, Richard , Voog, Éric , Zhang, Jingsong , Piulats, Josep M. , Ryan, Charles J. , Merseburger, Axel S. , Daugaard, Gedske , Heidenreich, Axel , Fizazi, Karim , Higano, Celestia S. , Krieger, Laurence E. , Watkins, Simon P. , Despain, Darrin , Simmons, Andrew D. , Loehr, Andrea , Dowson, Melanie, Golsorkhi, Tony, Chowdhury, Simon, investigators, on behalf of the TRITON2, Bryce, Alan H , Watkins, Simon P , Daugaard, Gedske , McDermott, Ray , Patnaik, Akash , Vogelzang, Nicholas J. , Sternberg, Cora N , investigators, on behalf of the TRITON2

Mayo Clinic

Journal of Clinical Oncology | August 14, 2020 | Volume: 38 | Issue: 32 | Pages: 3763-3772

10.1200/jco.20.01035 | PMID 32795228 Get It

PURPOSE BRCA1 or BRCA2 ( BRCA) alterations are common in men with metastatic castration-resistant prostate cancer (mCRPC) and may confer sensitivity to poly(ADP-ribose) polymerase inhibitors. We present results from patients with mCRPC associated with a BRCA alteration treated with rucaparib 600 mg twice daily in the phase II TRITON2 study. METHODS We enrolled patients who progressed after one to two lines of next-generation androgen receptor–directed therapy and one taxane-based chemotherapy for mCRPC. Efficacy and safety populations included patients with a deleterious BRCA alteration who received ≥ 1 dose of rucaparib. Key efficacy end points were objective response rate (ORR; per RECIST/Prostate Cancer Clinical Trials Working Group 3 in patients with measurable disease as assessed by blinded, independent radiology review and by investigators) and locally assessed prostate-specific antigen (PSA) response (≥ 50% decrease from baseline) rate. RESULTS Efficacy and safety populations included 115 patients with a BRCA alteration with or without measurable disease. Confirmed ORRs per independent radiology review and investigator assessment were 43.5% (95% CI, 31.0% to 56.7%; 27 of 62 patients) and 50.8% (95% CI, 38.1% to 63.4%; 33 of 65 patients), respectively. The confirmed PSA response rate was 54.8% (95% CI, 45.2% to 64.1%; 63 of 115 patients). ORRs were similar for patients with a germline or somatic BRCA alteration and for patients with a BRCA1 or BRCA2 alteration, while a higher PSA response rate was observed in patients with a BRCA2 alteration. The most frequent grade ≥ 3 treatment-emergent adverse event was anemia (25.2%; 29 of 115 patients). CONCLUSION Rucaparib has antitumor activity in patients with mCRPC and a deleterious BRCA alteration, but with a manageable safety profile consistent with that reported in other solid tumor types.
Clinical activity of pembrolizumab in metastatic prostate cancer with microsatellite instability high (MSI-H) detected by circulating tumor DNA
Barata, Pedro C. , Agarwal, Neeraj , Gerendash, Benjamin, Jaeger, Ellen , Hatton, Whitley, Lewis, Brian, Layton, Jodi Lyn , Bryce, Alan H. , Garje, Rohan , Stein, Cy A., Kiedrowski, Lesli A. , Saylor, Philip J. , Barata, Pedro , Bryce, Alan, Garje, Rohan , Bryce, Alan H , Agarwal, Archana M , Jaeger, Ellen B , Nussenzveig, Roberto , Ledet, Elisa M. , Babiker, Hani M. , Sartor, Oliver

Mayo Clinic

Journal for ImmunoTherapy of Cancer | August 12, 2020 | Volume: 8 | Issue: 2 | Pages: e001065

10.1136/jitc-2020-001065 | PMID 32788235 Get It

To report a multi-institutional case series of patients with advanced microsatellite instability high (MSI-H) prostate adenocarcinoma identified with clinical cell-free DNA (cfDNA) next-generation sequencing (NGS) testing and treated with immune checkpoint inhibitors. Retrospective analysis of patients with metastatic castration-resistant prostate cancer (mCRPC) and MSI-H tumor detected by a commercially available cfDNA NGS assay Guardant360 (G360, Guardant Health) at eight different Academic Institutions in the USA, from September 2018 to April 2020. From a total of 14 MSI-H metastatic prostate cancer patients at participating centers, nine patients with mCRPC with 56% bone, 33% nodal, 11% liver and 11% soft-tissue metastases and a median PSA of 29.3 ng/dL, were treated with pembrolizumab after 2 lines of therapy for CRPC. The estimated median time on pembrolizumab was 9.9 (95% CI 1.0 to 18.8) months. Four patients (44%) achieved PSA50 after a median of 4 (3–12) weeks after treatment initiation including three patients with >99% PSA decline. Among the patients evaluable for radiographic response (n=5), the response rate was 60% with one complete response and two partial responses. Best response was observed after a median of 3.3 (1.4–7.6) months. At time of cut-off, four patients were still on pembrolizumab while four patients discontinued therapy due to progressive disease and one due to COVID-19 infection. Half of the patients with PSA50 had both MSI-H and pathogenic alterations in BRCA1 and BRCA2 in their G360 assays. The use of liquid biopsy to identify metastatic prostate cancer patients with MSI-H is feasible in clinical practice and may overcome some of the obstacles associated with prostate cancer tumor tissue testing. The robust activity of pembrolizumab in selected patients supports the generalized testing for MSI-H.
Incremental benefit of a novel signal recording system during mapping and ablation
Padmanabhan, Deepak , Sugrue, Alan , Vaidya, Vaibhav R. , Witt, Chance M. , Yasin, Omar , Naksuk, Niyada , Killu, Ammar M. , Foxall, T., Drakulic, Budimir , Venkatachalam, K, Asirvatham, Samuel J. , Vaidya, Vaibhav, Witt, Chance, Killu, Ammar, Venkatachalam, Kalapathi Lakshminarayana, Asirvatham, Samuel J , Foxall, Thomas

Mayo Clinic

EP Europace | August 10, 2020 | Volume: 23 | Issue: 1 | Pages: 130-138

10.1093/europace/euaa194 | PMID 33094311 Get It

Abstract Aims Current electrophysiology signal recording and mapping systems have limited dynamic range (DR) and bandwidth, which causes loss of valuable information during acquisition of cardiac signals. We evaluated a novel advanced signal processing platform with the objective to obtain and assess additional information of clinical importance. Methods and results Over 10 canines, we compared intracardiac recordings within all cardiac chambers, in various rhythms, in pacing and during radiofrequency (RF) ablation across two platforms; a conventional system and the PURE EP™ [(PEP); Bio Sig Technologies, Inc., Los Angeles, CA, USA]. Recording cardiac signals with varying amplitudes were consistently and reproducibly observed, without loss of detail or introduction of artefact. Further the amplitude of current of injury (COI) on the unipolar signals correlated with the instantaneous contact force (CF) recorded on the sensing catheter in all the animals (r2 = 0.94 in ventricle). The maximum change in the unipolar COI correlated with the change in local electrogram amplitude during non-irrigated RF ablation (r2 = 0.61 in atrium). Reduction in artefact attributable to pacing (20 sites) and noise during ablation (48 sites) was present on the PEP system. Within the PEP system, simultaneous display of identical signals, filtered differently, aided the visualization of discrete conduction tissue signals. Conclusion Compared to current system, the PEP system provided incremental information including identifying conduction tissue signals, estimates of CF and a surrogate for lesion formation. This novel signal processing platform with increased DR and minimal front-end filtering may be useful in clinical practice.
Combining BRAF inhibition with oncolytic herpes simplex virus enhances the immune-mediated antitumor therapy of BRAF-mutant thyroid cancer
Crespo-Rodriguez, Eva, Bozhanova, Galabina, Foo, Shane , Patin, Emmanuel C. , Whittock, Harriet, Muirhead, Gareth, Thway, Khin , Newbold, Kate, Coffin, Robert S., Vile, Richard G. , Melcher, Alan , Harrington, Kevin J. , Pedersen, Malin , Pedersen, Malin , Melcher, Alan A , Harrington, Kevin , Bergerhoff, Katharina F. , Buus, Richard , Haider, Syed Aleem , Kim, Dae Joon , McLaughlin, Martin

Mayo Clinic

Journal for ImmunoTherapy of Cancer | August 6, 2020 | Volume: 8 | Issue: 2 | Pages: e000698

10.1136/jitc-2020-000698 | PMID 32759235 Get It

Background The aggressive clinical behavior of poorly differentiated and anaplastic thyroid cancers (PDTC and ATC) has proven challenging to treat, and survival beyond a few months from diagnosis is rare. Although 30%–60% of these tumors contain mutations in the BRAF gene, inhibitors designed specifically to target oncogenic BRAF have shown limited and only short-lasting therapeutic benefits as single agents, thus highlighting the need for improved treatment strategies, including novel combinations. Methods Using a BRAFV600E-driven mouse model of ATC, we investigated the therapeutic efficacy of the combination of BRAF inhibition and oncolytic herpes simplex virus (oHSV). Analyses of samples from tumor-bearing mice were performed to immunologically characterize the effects of different treatments. These immune data were used to inform the incorporation of immune checkpoint inhibitors into triple combination therapies. Results We characterized the immune landscape in vivo following BRAF inhibitor treatment and detected only modest immune changes. We, therefore, hypothesized that the addition of oncolytic virotherapy to BRAF inhibition in thyroid cancer would create a more favorable tumor immune microenvironment, boost the inflammatory status of tumors and improve BRAF inhibitor therapy. First, we showed that thyroid cancer cells were susceptible to infection with oHSV and that this process was associated with activation of the immune tumor microenvironment in vivo. Next, we showed improved therapeutic responses when combining oHSV and BRAF inhibition in vivo, although no synergistic effects were seen in vitro, further confirming that the dominant effect of oHSV in this context was likely immune-mediated. Importantly, both gene and protein expression data revealed an increase in activation of T cells and natural killer (NK) cells in the tumor in combination-treated samples. The benefit of combination oHSV and BRAF inhibitor therapy was abrogated when T cells or NK cells were depleted in vivo. In addition, we showed upregulation of PD-L1 and CTLA-4 following combined treatment and demonstrated that blockade of the PD-1/PD-L1 axis or CTLA-4 further improved combination therapy. Conclusions The combination of oHSV and BRAF inhibition significantly improved survival in a mouse model of ATC by enhancing immune-mediated antitumor effects, and triple combination therapies, including either PD-1 or CTLA-4 blockade, further improved therapy.
ADAM10 mediates ectopic proximal tubule development and renal fibrosis through Notch signalling
Li, Bingjue, Zhu, Chaohong, Dong, Lihua , Xiang, Wenyu, Davidson, Alan J. , Feng, Shi , Wang, Yucheng , Shen, Xiujin , Weng, Chunhua , Teng, Lisha, Wang, Junwen , Chen, Jianghua , Jiang, Hong , Chen, Jianghua , Jiang, Hong , Wang, Junwen , Qin, Jing , Wang, Cuili , Zhu, Tingting, Englert, Christoph

Mayo Clinic

The Journal of Pathology | July 27, 2020 | Volume: 252 | Issue: 3 | Pages: 274-289

10.1002/path.5517 | PMID 32715474 Get It

AbstractDisturbed intrauterine development increases the risk of renal disease. Various studies have reported that Notch signalling plays a significant role in kidney development and kidney diseases. A disintegrin and metalloproteinase domain 10 (ADAM10), an upstream protease of the Notch pathway, is also reportedly involved in renal fibrosis. However, how ADAM10 interacts with the Notch pathway and causes renal fibrosis is not fully understood. In this study, using a prenatal chlorpyrifos (CPF) exposure mouse model, we investigated the role of the ADAM10/Notch axis in kidney development and fibrosis. We found that prenatal CPF‐exposure mice presented overexpression of Adam10, Notch1 and Notch2, and led to premature depletion of Six2+ nephron progenitors and ectopic formation of proximal tubules (PTs) in the embryonic kidney. These abnormal phenotypic changes persisted in mature kidneys due to the continuous activation of ADAM10/Notch and showed aggravated renal fibrosis in adults. Finally, both ADAM10 and NOTCH2 expression were positively correlated with the degree of renal interstitial fibrosis in IgA nephropathy patients, and increased ADAM10 expression was negatively correlated with decreased kidney function evaluated by serum creatinine, cystatin C, and estimated glomerular filtration rate. Regression analysis also indicated that ADAM10 expression was an independent risk factor for fibrosis in IgAN. © 2020 The Authors. The Journal of Pathology published by John Wiley & Sons, Ltd. on behalf of The Pathological Society of Great Britain and Ireland.
Characterization of the ‘White’ Appearing Clots that Cause Acute Ischemic Stroke
Mereuta, Oana Madalina , Douglas, Andrew , McCarthy, Ray, Gilvarry, Michael , Brinjikji, Waleed , Kallmes, David F. , O’Hare, Alan , Power, Sarah , Alderson, Jack , Murphy, Blathnaid , Davidson, Maria, Brederlau, Anke, Allardt, Arne , Thornton, John , Doyle, Karen , Madalina Mereuta, Oana , Fitzgerald, Seán , Rossi, Rosanna , Pandit, Abhay , Brennan, Paul, Gunnarsson, Þorsteinn , Tatlisumak, Turgut , Rentzos, Alexandros

Mayo Clinic

No container title available | July 24, 2020 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-45700/v1 Get It

Abstract Background: Most clots retrieved from patients with acute ischemic stroke are ‘red’ in color and are predominantly composed of red blood cells and fibrin. ‘White’ clots represent a less common entity and their histological composition is largely unknown.The aim of this study was to investigate the composition, imaging and procedural characteristics of ‘white’ clots retrieved by mechanical thrombectomy.Materials and Methods:Nineteen ‘white’ thrombi selected by visual inspection from 293 cases were collected as part of the multi-institutional RESTORE registry. Non-contrast computed tomography (NCCT), histological and immunohistochemical analyses were performed. Components were quantified using Orbit Image Analysis.Results:Quantification of Martius Scarlett Blue stain identified platelets/other as the major component in ‘white’ clots’ (63%) followed by fibrin (26%), red blood cells (7%) and white blood cells (4%). ‘White’ clots presented significantly more platelets/other and less red blood cells compared to the ‘red’ clots which showed a mean of 23% and 44%, respectively. The mean platelet (CD42b) content in ‘white’ clots was 43%; von Willebrand Factor (vWF) mean expression was 38%.Collagen and calcification were associated in one case. Fatty acid binding protein 4 was expressed in two cases.‘White’ clots were also significantly smaller (9.5 versus 12 mm) and less hyperdense (52 versus 61 Hounsfield Units) on NCCT compared to the other cases.Conclusions:‘White’ clots represented 6% of our cohort and are platelet and vWF-rich. Calcification, collagen and adipocytes were found occasionally. ‘White’ clots differ from other clots in composition, size and density on NCCT.
Genome-Wide Association Study Meta-Analysis of Stroke in 22 000 Individuals of African Descent Identifies Novel Associations With Stroke
Keene, Keith L. , Hyacinth, Hyacinth I. , Bis, Joshua C. , Kittner, Steven J. , Cheng, Yu-Ching , O’Donnell, Martin , Chen, Wei‐Min , Sale, Michèle M. , Rich, Stephen S. , Nalls, Mike A., Wilson, James G. , Markus, Hugh S. , Lewis, Cathryn M. , Carty, Cara L. , Reiner, Alex P. , Haessler, Jeff, Langefeld, Carl D. , Gottesman, Rebecca F., Woo, Daniel , Yaffe, Kristine , Liu, YongMei, Longstreth, W.T. , Kooperberg, Charles, Lange, Leslie A., Sacco, Ralph L., Cruchaga, Carlos , Furie, Karen L., Arnett, Donna K. , Benavente, Oscar, Grewal, Raji P., Peddareddygari, Leema Reddy , Dichgans, Martin , Worrall, Bradford B. , Fornage, Myriam , Consortia, on behalf of the COMPASS, SiGN, and METASTROKE, Dichgans, Martin , Cruchaga, Carlos , Rich, Stephen S , Arnett, Donna K , Lewis, Cathryn M , Mitchell, Braxton D. , Paré, Guillaume , Chong, Michael , Meschia, James F. , Zonderman, Alan B. , Evans, Michele K. , Correa, Adolfo , Traylor, Matthew , Mosley, Thomas H. , Psaty, Bruce M. , Rundek, Tatjana , Lee, Jin‐Moo , Malik, Rainer , Consortia, on behalf of the COMPASS, SiGN, and METASTROKE

Mayo Clinic

Stroke | July 22, 2020 | Volume: 51 | Issue: 8 | Pages: 2454-2463

10.1161/strokeaha.120.029123 | PMID 32693751 Get It

Background and Purpose: Stroke is a complex disease with multiple genetic and environmental risk factors. Blacks endure a nearly 2-fold greater risk of stroke and are 2× to 3× more likely to die from stroke than European Americans. Methods: The COMPASS (Consortium of Minority Population Genome-Wide Association Studies of Stroke) has conducted a genome-wide association meta-analysis of stroke in >22 000 individuals of African ancestry (3734 cases, 18 317 controls) from 13 cohorts. Results: In meta-analyses, we identified one single nucleotide polymorphism (rs55931441) near the HNF1A gene that reached genome-wide significance ( P =4.62×10 −8 ) and an additional 29 variants with suggestive evidence of association ( P <1×10 −6 ), representing 24 unique loci. For validation, a look-up analysis for a 100 kb region flanking the COMPASS single nucleotide polymorphism was performed in SiGN (Stroke Genetics Network) Europeans, SiGN Hispanics, and METASTROKE (Europeans). Using a stringent Bonferroni correction P value of 2.08×10 −3 (0.05/24 unique loci), we were able to validate associations at the HNF1A locus in both SiGN ( P =8.18×10 −4 ) and METASTROKE ( P =1.72×10 −3 ) European populations. Overall, 16 of 24 loci showed evidence for validation across multiple populations. Previous studies have reported associations between variants in the HNF1A gene and lipids, C-reactive protein, and risk of coronary artery disease and stroke. Suggestive associations with variants in the SFXN4 and TMEM108 genes represent potential novel ischemic stroke loci. Conclusions: These findings represent the most thorough investigation of genetic determinants of stroke in individuals of African descent, to date.